Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
Authors' conclusion
Vaccine boosters improve humoral immune responses and are safe in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
Study context
- Population
- Adults ≥18 years with IMIDs (RA, SpA, PsA, Crohn's disease, ulcerative colitis) on immunosuppressive therapy, Oslo and Lørenskog, Norway
- Participants
- 703 eligible patients
- Exposure
- Four SARS-CoV-2 vaccine doses vs three doses followed by COVID-19 (hybrid) vs healthy controls with three doses
- Vaccinen = 536
- Hybridn = 167
- Outcome
- Anti-RBD antibody concentrations
- Follow-up
- 2-4 weeks following vaccination or COVID-19
Methodological detailsprospective observational, multicentre
- Prospective observational
- Multicentre
Main finding
As reported in the abstract
Anti-RBD antibody concentration · 2-4 weeks
Vaccine
6192
median · IQR 2878-11 243 · BAU/ml
Hybrid
23 548
IQR 11 440-35 935 · BAU/ml
Control
7595
median · IQR 5916-12 001 · BAU/ml
Vaccine vs Control: P < 0.0001 · Hybrid vs Vaccine: P < 0.0001
Observational data: associations, not effects.
Further findings
- Anti-RBD antibodies after third dose, vaccine group (vs fourth dose)
- 5087 · median · IQR 1250–9081 · BAU/ml
- Anti-RBD antibodies after third dose, vaccine group (vs fourth dose) — Higher after fourth than after third dose
- p< 0.0001
Fourth dose BNT162b2 (full-dose) vs mRNA-1273 (half-dose)
- No difference in antibody concentrations
Original publication
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study. Lancet Rheumatol. Published 16 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →